This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Elizabeth Pham, PhD
Principal Scientist at Amgen


Dr. Elizabeth Pham holds a Ph.D in Biomedical Engineering from the University of Toronto and performed post-doctoral research at Sunnybrook Research Institute prior to joining Oncology Discovery Research at Amgen Inc. She is currently a Principal Scientist heading a research group at Amgen focused on target discovery and BiTE® molecule development for solid tumors

Agenda Sessions

  • AMG 794, A Claudin 6-Targeted Half-life Extended (HLE) Bispecific T Cell Engager (BITE®) Molecule for Non-small Cell Lung Cancer and Epithelial Ovarian Cancer